Literature DB >> 27331632

Mortality due to Respiratory Syncytial Virus. Burden and Risk Factors.

Sarah Geoghegan1, Anabella Erviti1, Mauricio T Caballero1, Fernando Vallone2, Stella M Zanone1, Juan Ves Losada3, Alejandra Bianchi1, Patricio L Acosta1, Laura B Talarico1, Adrian Ferretti1, Luciano Alva Grimaldi4, Andrea Sancilio5, Karina Dueñas5, Gustavo Sastre6, Andrea Rodriguez6, Fernando Ferrero7, Edgar Barboza8, Guadalupe Fernández Gago9, Celina Nocito10, Edgardo Flamenco11, Alberto Rodriguez Perez12, Beatriz Rebec13, F Martin Ferolla1, Romina Libster1, Ruth A Karron14, Eduardo Bergel1, Fernando P Polack1,15.   

Abstract

RATIONALE: Respiratory syncytial virus (RSV) is the most frequent cause of hospitalization and an important cause of death in infants in the developing world. The relative contribution of social, biologic, and clinical risk factors to RSV mortality in low-income regions is unclear.
OBJECTIVES: To determine the burden and risk factors for mortality due to RSV in a low-income population of 84,840 infants.
METHODS: This was a prospective, population-based, cross-sectional, multicenter study conducted between 2011 and 2013. Hospitalizations and deaths due to severe lower respiratory tract illness (LRTI) were recorded during the RSV season. All-cause hospital deaths and community deaths were monitored. Risk factors for respiratory failure (RF) and mortality due to RSV were assessed using a hierarchical, logistic regression model.
MEASUREMENTS AND MAIN RESULTS: A total of 2,588 (65.5%) infants with severe LRTI were infected with RSV. A total of 157 infants (148 postneonatal) experienced RF or died with RSV. RSV LRTI accounted for 57% fatal LRTI tested for the virus. A diagnosis of sepsis (odds ratio [OR], 17.03; 95% confidence interval [CI], 13.14-21.16 for RF) (OR, 119.39; 95% CI, 50.98-273.34 for death) and pneumothorax (OR, 17.15; 95% CI, 13.07-21.01 for RF) (OR, 65.49; 95% CI, 28.90-139.17 for death) were the main determinants of poor outcomes.
CONCLUSIONS: RSV was the most frequent cause of mortality in low-income postneonatal infants. RF and death due to RSV LRTI, almost exclusively associated with prematurity and cardiopulmonary diseases in industrialized countries, primarily affect term infants in a developing world environment. Poor outcomes at hospitals are frequent and associated with the cooccurrence of bacterial sepsis and clinically significant pneumothoraxes.

Entities:  

Keywords:  bacterial superinfections; mortality; pneumothorax; respiratory syncytial virus

Mesh:

Year:  2017        PMID: 27331632     DOI: 10.1164/rccm.201603-0658OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  40 in total

1.  Upregulation of CD32 in T Cells from Infants with Severe Respiratory Syncytial Virus Disease: A New Costimulatory Pathway?

Authors:  Inés Sananez; Silvina Raiden; María P Holgado; Vanesa Seery; Leonardo De Lillo; Carolina Davenport; Fernando Ferrero; Mark E Peeples; Jorge Geffner; Lourdes Arruvito
Journal:  Am J Respir Cell Mol Biol       Date:  2020-07       Impact factor: 6.914

Review 2.  Ongoing developments in RSV prophylaxis: a clinician's analysis.

Authors:  Fariba Rezaee; Debra T Linfield; Terri J Harford; Giovanni Piedimonte
Journal:  Curr Opin Virol       Date:  2017-05-10       Impact factor: 7.090

3.  Maternal RSV vaccine development. Where to from here?

Authors:  Ahinsa Gunatilaka; Michelle L Giles
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

4.  Changes in Critical Bronchiolitis After COVID-19 Lockdown.

Authors:  Jose Cardenas; Charlene Pringle; Stephanie L Filipp; Matthew J Gurka; Kathleen A Ryan; K Leslie Avery
Journal:  Cureus       Date:  2022-05-17

Review 5.  Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

Authors:  Luis Garegnani; Lea Styrmisdóttir; Pablo Roson Rodriguez; Camila Micaela Escobar Liquitay; Ignacio Esteban; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-11-16

6.  Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.

Authors:  Elizabeth J McFarland; Ruth A Karron; Petronella Muresan; Coleen K Cunningham; Jennifer Libous; Charlotte Perlowski; Bhagvanji Thumar; Devasena Gnanashanmugam; Jack Moye; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Laura Fearn; Stephen A Spector; Mariam Aziz; Mikhaela Cielo; Christy Beneri; Andrew Wiznia; Cindy Luongo; Peter Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

7.  Bronchopulmonary dysplasia as a determinant of respiratory outcomes in adult life.

Authors:  Joseph M Collaco; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2021-03-17

8.  Epidemiology and factors associated with the severity of viral acute lower respiratory infection in children hospitalized in Manaus, Amazonas, in 2017-2018: An observational study.

Authors:  Fabrícia L D V Sobrinho; Davi C Aragon; Ana P C P Carlotti
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

9.  Respiratory Syncytial Virus (RSV) Infects CD4+ T Cells: Frequency of Circulating CD4+ RSV+ T Cells as a Marker of Disease Severity in Young Children.

Authors:  Silvina Raiden; Inés Sananez; Federico Remes-Lenicov; Julieta Pandolfi; Cecilia Romero; Leonardo De Lillo; Ana Ceballos; Jorge Geffner; Lourdes Arruvito
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

Review 10.  Pathophysiology of COVID-19: Why Children Fare Better than Adults?

Authors:  Nitin Dhochak; Tanu Singhal; S K Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2020-05-14       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.